Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Van den Berg, Sylvia![]() |
|
dc.contributor.author | Van Rooyen, Cathy![]() |
|
dc.contributor.author | Wessels, Pieter Frederik![]() |
|
dc.contributor.author | Brauer, Marieke![]() |
|
dc.contributor.author | Green, Robin J.![]() |
|
dc.date.accessioned | 2023-05-23T05:02:41Z | |
dc.date.available | 2023-05-23T05:02:41Z | |
dc.date.issued | 2022-03 | |
dc.description.abstract | Patients rely on healthcare providers as their most credible and frequent source of vaccine information. It is therefore crucial that healthcare providers are informed and have evidence-based, objective and clear guidance on vaccine efficacy and specific adverse events following immunisation (AEFI). Reported serious AEFIs are extremely rare for the COVID-19 vaccines. This article discusses the main AEFIs attributed to COVID-19 vaccines, including neurological complications of Guillain-Barré syndrome (GBS) and acute transverse myelitis (ATM), thrombosis; cardiac complications, including myocarditis, pericarditis and cardiomyopathy; and allergic reactions such as anaphylaxis, urticaria and skin rashes. The benefits of COVID-19 vaccination outweigh the risks; however, it is important that healthcare providers are aware of the risks and know how to recognise and manage them. | en_US |
dc.description.department | Paediatrics and Child Health | en_US |
dc.description.librarian | am2023 | en_US |
dc.description.uri | https://journals.co.za/journal/caci | en_US |
dc.identifier.citation | Van den Berga, S., Van Rooyen, C., Wessels, P.F. et al. 2022, 'COVID-19 vaccines : adverse events following immunisation', Current Allergy and Clinical Immunology, vol. 35, no. 1, pp. 16-22, doi : 10.520/ejc-caci-v35-n1-a3. | en_US |
dc.identifier.issn | 1609-3607 (print) | |
dc.identifier.other | 10.520/ejc-caci-v35-n1-a3 | |
dc.identifier.uri | http://hdl.handle.net/2263/90777 | |
dc.language.iso | en | en_US |
dc.publisher | Allergy Society of South Africa | en_US |
dc.rights | © Allergy Society of South Africa. | en_US |
dc.subject | COVID-19 vaccine | en_US |
dc.subject | Adverse events | en_US |
dc.subject | Guillain-Barré syndrome (GBS) | en_US |
dc.subject | Acute transverse myelitis (ATM) | en_US |
dc.subject | Thrombosis | en_US |
dc.subject | Cardiac complications | en_US |
dc.subject | Myocarditis | en_US |
dc.subject | Pericarditis | en_US |
dc.subject | Cardiomyopathy | en_US |
dc.subject | Vaccine allergy | en_US |
dc.subject | Urticarial | en_US |
dc.subject | Skin rash | en_US |
dc.subject | COVID-19 pandemic | en_US |
dc.subject | Coronavirus disease 2019 (COVID-19) | en_US |
dc.title | COVID-19 vaccines : adverse events following immunisation | en_US |
dc.type | Article | en_US |